Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01248169 · ClinicalTrials.gov registry record
Impedance Cardiographic (ICG) Assessment of Pregnant Women With Severe Hypertension to Assess Impact of Standard Therapy
A clinical trial of Pregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) and Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe), sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT01248169: Completed study of Pregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) and Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe), sponsored by University of Mississippi Medical Center.
NCT01248169 is a study of Pregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) and Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe) that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01248169, a study of Pregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) and Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe), has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The utilization of external cardiohemodynamic patient assessment, applying non-invasive stick-on contact patches to the mother's neck on either side and chest wall on either side, enables the practitioner to have information about the patient's cardiac function and vascular status beyond simply blood pressure and pulse. This information, once collected, should open the practitioner's eyes to better assess the patient's disease status and her response to therapy. We will use this information to compare the effectiveness of the two standard medications used for treatment of maternal high blood pressure.
Primary Outcome
ICG test is performed on pregnant women before receiving any antihypertensive medication. Labetalol and Hydralazine, two ot the most commonly used antihypertensives to treat high blood pressure in pregnant women will be used in this study.
Conditions Studied
Study Locations (1)
Mississippi
- Wiser Hospital for Women and Infants at the University of Mississippi Medical Center - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-11 |
What the finished NCT01248169 record still lists
NCT01248169 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 3 conditions, with Pregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) appearing as the primary indexed condition, and to 0 interventions.
NCT01248169 reports a single indexed study location in Mississippi.
Frequently Asked Questions
What is clinical trial NCT01248169 about?
NCT01248169 is a clinical study titled "Impedance Cardiographic (ICG) Assessment of Pregnant Women With Severe Hypertension to Assess Impact of Standard Therapy". The utilization of external cardiohemodynamic patient assessment, applying non-invasive stick-on contact patches to the mother's neck on either side and chest wall on either side, enables the practitioner to have information about the patient's cardiac function and vascular status beyond simply bloo...
What is the current status of trial NCT01248169?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2009-12. Estimated completion is 2013-11.
What conditions does trial NCT01248169 study?
This clinical trial studies the following conditions: Pregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia), Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe), Pregnancy; Hypertension, Gestational Hypertension, With Albuminuria (Severe Pre-eclampsia).
Who is sponsoring clinical trial NCT01248169?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01248169 being conducted?
This trial has 1 study location across Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia